Jpmorgan Chase & CO 2seventy Bio, Inc. Put Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding TSVT
# of Institutions
121Shares Held
48.1MCall Options Held
211KPut Options Held
9.7K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$26.9 Million1.78% of portfolio
-
Goldman Sachs Group Inc New York, NY4.14MShares$18.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$16.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$16.4 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.27MShares$14.8 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $171M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...